{"id":"W4389029223","doi":"10.1016/j.ajt.2026.04.010","title":"920. A Phase 2 Multi-Center, Prospective, Randomized, Double-Blind Study to Assess the Clinical and Antiviral Efficacy and Safety of Nitazoxanide for the Treatment of Norovirus in Hematopoietic Stem Cell and Solid Organ Transplant Recipients","year":2023,"lang":"en","type":"article","venue":"American Journal of Transplantation","topic":"Viral gastroenteritis research and epidemiology","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université de Montréal","funders":"Astellas Pharma; Moderna; Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases; Cidara Therapeutics; Regeneron Pharmaceuticals; Medpace; National Institute of Allergy and Infectious Diseases; Pfizer; Bristol-Myers Squibb; National Institutes of Health; U.S. Department of Health and Human Services","keywords":"Medicine; Norovirus; Nitazoxanide; Clinical endpoint; Placebo; Internal medicine; Population; Adverse effect; Randomization; Viral load; Diarrhea; Randomized controlled trial; Clinical trial; Gastroenterology; Immunology; Human immunodeficiency virus (HIV); Virus","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002436138,0.001383434,0.002081183,0.0004329888,0.0004586321,0.0007082468,0.000625372,0.001331744,0.006472091],"category_scores_gemma":[0.001489708,0.0007728327,0.000843422,0.0003654724,0.0009689305,0.0008439163,0.0003042479,0.002151602,0.001157193],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004328942,"about_ca_system_score_gemma":0.001336281,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004409271,"about_ca_topic_score_gemma":0.00126269,"domain_scores_codex":[0.9989607,0.0006477084,0.00006466323,0.000129559,0.00008156062,0.0001157862],"domain_scores_gemma":[0.9991463,0.0002027688,0.0001882278,0.00007068391,0.00007442137,0.0003175583],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9539608,0.02088253,0.001267951,0.0003888162,0.0004097371,0.00004306128,0.00004559004,0.0001651767,0.01016189,0.000113001,0.000709923,0.01185155],"study_design_scores_gemma":[0.8522771,0.1439556,0.002119663,0.00001372807,0.0001606857,0.00002402003,0.000009778269,0.0002334667,0.0006000456,0.00004982166,0.0005474391,0.000008666924],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9832367,0.001942652,0.001084635,0.0003696148,0.0003391922,0.00950097,0.00152657,0.0001337968,0.001865724],"genre_scores_gemma":[0.973192,0.001915127,0.003649692,0.001431047,0.0004731788,0.01327069,0.001856153,0.00003448095,0.004177493],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006472091,"threshold_uncertainty_score":0.02165127,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09524816972908962,"score_gpt":0.4336699148575565,"score_spread":0.3384217451284668,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}